{"gene":"TNFSF12","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2001,"finding":"TWEAK binds a novel TNF receptor superfamily member (TweakR/Fn14) cloned from a human umbilical vein endothelial cell library; the interaction has an affinity constant (Kd) of 2.3 ± 0.1 nM as measured by five independent binding assays. The TweakR cytoplasmic domain binds TRAFs 1, 2, and 3. Cross-linking of TweakR induces HUVEC growth, and soluble TweakR inhibits endothelial cell migration in vitro and corneal angiogenesis in vivo.","method":"Receptor cloning, five binding assays, TRAF pulldown/binding assays, HUVEC proliferation and migration assays, in vivo corneal angiogenesis model","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1 / Strong — receptor cloning with multiple orthogonal binding assays, TRAF interaction, functional in vitro and in vivo validation in a single rigorous study","pmids":["11728344"],"is_preprint":false},{"year":1999,"finding":"TWEAK-induced apoptosis in Kym-1 cells is indirect, mediated by endogenous TNF signaling through TNFR1; TNFR1-Fc fusion protein, neutralizing anti-TNF antibodies, and TNFR1-specific Fab fragments each blocked cell death. TWEAK also co-stimulates TNFR1-mediated cell death. Kym-1 cells do not express DR3/APO3 at protein or mRNA level, indicating a separate, undefined non-death-domain TWEAK receptor.","method":"Neutralizing antibody blockade, TNFR1-Fc fusion protein, flow cytometry binding assay, RT-PCR for receptor expression","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal blocking approaches in a single study establishing indirect TNF-mediated mechanism","pmids":["10382740"],"is_preprint":false},{"year":2002,"finding":"TWEAK induces multiple cell-death pathways in a cell-type-specific manner: (1) caspase-8 and caspase-3 dependent apoptosis in HSC3 cells; (2) cathepsin B-dependent necrosis in IFN-γ-treated HT-29 cells, accompanied by cytosolic release of cathepsin B from lysosomes. Pan-caspase inhibition switches HT-29 death to necrosis. None of the TWEAK-sensitive lines express DR3, confirming TWEAK acts through a receptor distinct from DR3.","method":"Caspase activity assays, caspase and lysosomal proteinase inhibitors, cathepsin B subcellular fractionation, flow cytometry receptor binding, RT-PCR and western for DR3","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple cell lines, enzymatic activity assays with pharmacological inhibitors, and subcellular fractionation identifying mechanistic bifurcation","pmids":["11777967"],"is_preprint":false},{"year":2005,"finding":"TWEAK selectively stimulates proliferation of liver oval (progenitor) cells but has no mitogenic effect on mature hepatocytes. This mitogenic activity is mediated through the Fn14 receptor: TWEAK-expressing adenovirus induces oval cell expansion in wild-type but not Fn14-null mice, and a blocking anti-TWEAK mAb reduces DDC-induced oval cell expansion.","method":"Transgenic mouse overexpression, Fn14-null mouse genetic model, adenoviral TWEAK delivery, anti-TWEAK blocking mAb, oval cell culture proliferation assay","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic (Fn14-KO) and antibody blocking approaches combined with in vitro proliferation assay, replicated across multiple experimental models","pmids":["16110324"],"is_preprint":false},{"year":2007,"finding":"CD163, a scavenger receptor on monocytes/macrophages, binds TWEAK with dose-dependent affinity. In competition assays, soluble CD163 and Fn14 competitively displace TWEAK from their respective coated binding partners. Monocytes (Fn14-negative, CD163-positive) can sequester TWEAK from supernatants, preventing tumor cell apoptosis; this was reversed by an anti-CD163 mAb or a CD163-mimicking peptide. Recombinant TWEAK binding to CD163-transfected CHO cells was inhibited by unlabeled TWEAK or Hp-Hb complex.","method":"Combinatorial peptide library screen, dose-dependent binding assay, competition binding assay, flow cytometry, immunofluorescence, CHO cell transfection binding assay, functional apoptosis assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal binding and functional assays in a single study establishing CD163 as an alternate TWEAK-binding protein","pmids":["17548657"],"is_preprint":false},{"year":2011,"finding":"TWEAK and TNFα reduce renal Klotho expression through an NF-κB-dependent mechanism: TWEAK activates NF-κB and promotes RelA binding to the Klotho promoter with accompanying histone deacetylation, as shown by chromatin immunoprecipitation. NF-κB inhibition with parthenolide and HDAC inhibitor treatment each reversed TWEAK-induced Klotho downregulation.","method":"Chromatin immunoprecipitation (ChIP), siRNA knockdown of IκBα, NF-κB and HDAC inhibitor pharmacology, in vivo TWEAK administration with TWEAK blockade/KO, tubular cell culture","journal":"Journal of the American Society of Nephrology","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP directly demonstrating RelA occupancy at Klotho promoter plus histone modification, corroborated by in vivo genetic and pharmacological approaches","pmids":["21719790"],"is_preprint":false},{"year":2012,"finding":"TWEAK at low concentrations preferentially activates the non-canonical NF-κB pathway and increases myoblast fusion. Loss of cIAP1 constitutively activates non-canonical NF-κB and amplifies fusion; knockdown of p100, RelB, IKKα, or NIK attenuates fusion in wild-type myoblasts, placing non-canonical NF-κB signaling downstream of TWEAK-Fn14 in the regulation of myoblast fusion.","method":"Genetic knockdown (siRNA), cIAP1 knockout cells, p52/RelB overexpression, TRAF3 depletion, NF-κB pathway component manipulation, multinucleation counting assay","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 / Strong — epistasis established by multiple genetic perturbations and rescue experiments in a single rigorous study","pmids":["23074266"],"is_preprint":false},{"year":2013,"finding":"TWEAK transactivates the EGFR in renal tubular cells via Fn14 binding, leading to ADAM17 activation and release of EGFR ligands HB-EGF and TGFα. EGFR transactivation drives ERK activation and proinflammatory gene upregulation, while NF-κB activation is EGFR-independent. In vivo, erlotinib (EGFR kinase inhibitor) and WTACE-2 (ADAM17 inhibitor) blocked TWEAK-induced renal EGFR phosphorylation and inflammation.","method":"In vivo TWEAK administration with erlotinib or ADAM17 inhibitor treatment, in vitro kinase inhibitor assays, western blotting for phospho-EGFR/ERK, anti-EGFR/ADAM17/ERK inhibitors","journal":"The Journal of pathology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mechanistic pathway dissection with multiple inhibitors in both in vitro and in vivo systems, identifying ADAM17 as the transactivation intermediate","pmids":["24037740"],"is_preprint":false},{"year":2016,"finding":"TWEAK decreases PGC-1α expression and mitochondrial function in renal tubular cells through an NF-κB-dependent mechanism involving histone H3 deacetylation at the PGC-1α promoter. Adenoviral PGC-1α overexpression prevents TWEAK-induced mitochondrial membrane potential loss. NF-κB or HDAC inhibitors prevented TWEAK-induced PGC-1α downregulation.","method":"Chromatin immunoprecipitation (H3 deacetylation at PGC-1α promoter), adenoviral PGC-1α overexpression rescue, NF-κB and HDAC pharmacological inhibitors, in vivo anti-TWEAK antibody treatment, mitochondrial membrane potential measurement","journal":"Kidney international","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP demonstrating epigenetic modification at PGC-1α promoter plus rescue by PGC-1α overexpression and pathway inhibition, validated in vivo","pmids":["26535995"],"is_preprint":false},{"year":2018,"finding":"TWEAK/Fn14 activation drives a second wave of necroptosis in acute kidney injury (AKI) at 72–96 h: TWEAK induces apoptosis in a proinflammatory environment in tubular cells, but caspase inhibition switches death to necroptosis. Genetic deficiency of RIPK3, MLKL, or Fn14, or treatment with necrostatin-1 (RIPK1 inhibitor), prevented late-phase cell death and renal dysfunction but not early injury (48 h).","method":"Genetic knockouts (RIPK3-KO, Fn14-KO), MLKL deficiency, necrostatin-1 pharmacology, folic acid-induced AKI mouse model, in vitro tubular cell death assays with caspase inhibition","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models plus pharmacological corroboration establishing TWEAK/Fn14-RIPK1 necroptosis axis with defined temporal window","pmids":["29588419"],"is_preprint":false},{"year":2018,"finding":"TRAF3IP2 mediates TWEAK/TWEAKR-induced pro-fibrotic responses in cardiac fibroblasts: forced TRAF3IP2 expression upregulates TWEAK and TWEAKR; exogenous TWEAK upregulates TRAF3IP2 in a dose/time-dependent manner (positive feedback). TRAF3IP2 silencing inhibits TWEAK-induced p38 MAPK, NF-κB and AP-1 activation, inflammatory cytokine expression, MMP/TIMP1, collagen secretion, and fibroblast proliferation/migration. TWEAK infusion in vivo induces cardiac TRAF3IP2, NF-κB/AP-1, fibrosis and dysfunction; genetic TRAF3IP2 ablation prevents these changes.","method":"siRNA silencing, forced expression, western blotting, in vivo TWEAK infusion with TRAF3IP2 knockout mice, collagen secretion assay, migration assay","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic (KO) and siRNA approaches in vitro and in vivo, multiple orthogonal readouts establishing TRAF3IP2 as a causal signaling intermediate","pmids":["29981796"],"is_preprint":false},{"year":2013,"finding":"TWEAK increases HMGB1 mRNA expression and protein secretion in monocyte/macrophage (THP-1) cells via Fn14 binding and NF-κB and PI3K pathway activation; this effect is restricted to M1 macrophages and not M2. TWEAK-induced HMGB1 in turn promotes MCP-1 secretion (blocked by HMGB1 siRNA). In vivo, systemic TWEAK injection in ApoE-/- mice elevated aortic HMGB1; anti-TWEAK antibodies reduced it.","method":"Blocking anti-Fn14 antibody, NF-κB and PI3K pharmacological inhibitors, HMGB1 siRNA, in vivo TWEAK injection and anti-TWEAK antibody treatment in ApoE-/- mice, ELISA, qPCR","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple inhibitors and siRNA knockdown in vitro with in vivo corroboration, single lab study","pmids":["23288170"],"is_preprint":false},{"year":2017,"finding":"TWEAK promotes pro-inflammatory cytokine secretion (IL-8, IL-6, RANTES, MCP-1) in activated hepatic stellate cells (LX-2) via concurrent NF-κB and STAT3 pathway activation; STAT3 and NF-κB interact with each other, and siRNA knockdown of either pathway component reduces cytokine output synergistically.","method":"siRNA knockdown of NF-κB and JAK2/STAT3 components, western blotting for phosphorylated signaling proteins, ELISA for cytokines, RT-PCR","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown of two parallel pathways with multiple cytokine readouts, single lab","pmids":["28411440"],"is_preprint":false},{"year":2016,"finding":"TWEAK upregulates endothelin-converting enzyme-1 (ECE-1) and endothelin-1 (ET-1) in endothelial cells via AP-1 (ERK1/2 and JNK pathways) and NF-κB transcriptional activation, demonstrated by ECE-1 promoter serial deletion assays, EMSA for AP-1/NF-κB binding, and pharmacological inhibitors of ERK1/2 (PD-98059), JNK (SP-600125), and NF-κB (PDTC). In vivo TWEAK administration elevated ET-1 and ECE-1 in mouse aorta/lung and induced transient hypertension.","method":"ECE-1 promoter deletion/transfection assays, EMSA, ERK/JNK/NF-κB pharmacological inhibitors, in vivo TWEAK injection, ELISA, qPCR, western blotting","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — promoter deletion mapping and EMSA mechanistically identify AP-1/NF-κB sites, corroborated in vivo, single lab","pmids":["28025386"],"is_preprint":false},{"year":2009,"finding":"TWEAK promotes ovarian cancer cell migration, invasion, and VEGF upregulation via NF-κB pathway activation: TWEAK treatment causes NF-κB nuclear translocation, and NF-κB inhibition (PDTC) suppresses TWEAK-induced VEGF expression and metastatic behavior in HO-8910PM cells.","method":"NF-κB nuclear translocation assay, NF-κB pharmacological inhibition (PDTC), VEGF protein measurement, migration/invasion assays","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with multiple functional readouts, single lab","pmids":["19398263"],"is_preprint":false},{"year":2018,"finding":"TWEAK/Fn14 activation promotes atrial myocyte hypertrophy (HL-1 cells) via JAK2/STAT3 signaling: TWEAK increased ANP and Troponin T expression and cell size; siRNA knockdown of JAK2 or STAT3 attenuated TWEAK-induced hypertrophy; Fn14 knockdown counteracted TWEAK effects.","method":"siRNA knockdown of JAK2, STAT3, and Fn14; western blotting for ANP and Troponin T; cell size measurement","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA epistasis of JAK2/STAT3 with multiple readouts, single lab, in vitro","pmids":["29971943"],"is_preprint":false},{"year":2014,"finding":"TWEAK induces RANKL surface expression on immature STRO-1+ human osteoblasts, providing a mechanism for TWEAK-mediated bone erosion in rheumatoid arthritis. Soluble TWEAK did not directly stimulate osteoclast formation from PBMCs (negative result for direct osteoclastogenesis).","method":"Flow cytometry for surface RANKL on osteoblasts, PBMC osteoclastogenesis assay with sTWEAK, immunohistochemistry for TWEAK/Fn14 in RA synovium","journal":"Arthritis research & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assay on primary human osteoblasts establishing RANKL induction; negative result for direct osteoclastogenesis explicitly noted; single lab","pmids":["21435232"],"is_preprint":false},{"year":2003,"finding":"Murine TWEAK is expressed as a functional cell-surface protein on TWEAK-transfected cells and is secreted by thioglycolate-elicited peritoneal macrophages; the secreted form is cytotoxic against Fn14-expressing target cells and is neutralized by an anti-murine TWEAK mAb (MTW-1).","method":"cDNA transfection, anti-TWEAK and anti-Fn14 mAb generation, flow cytometry, cytotoxicity assay, neutralization assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct demonstration of secretion and cytotoxic activity with mAb neutralization, single lab","pmids":["12821115"],"is_preprint":false},{"year":2003,"finding":"TWEAK is identified as a type II transmembrane protein that can be shed as a biologically active soluble form. Its only known signaling receptor is Fn14/TweakR, the smallest TNFR superfamily member, which signals via TRAF recruitment.","method":"Literature synthesis of cloning studies and binding characterization","journal":"Cytokine & growth factor reviews","confidence":"Medium","confidence_rationale":"Tier 3 / Strong — review summarizing prior experimental identification data; cited as a synthesis of established experimental findings from multiple labs","pmids":["12787562"],"is_preprint":false},{"year":2021,"finding":"In psoriasis, TWEAK strongly synergizes with TNF and IL-17A to upregulate psoriasis-associated genes (IL23A, IL36G, CXC chemokines) in human keratinocytes. Fn14 (TNFRSF12A), the TWEAK receptor, is expressed in keratinocytes; keratinocyte-specific deletion of Fn14 reduced imiquimod-induced skin inflammation and epidermal hyperplasia in mice.","method":"Keratinocyte-specific Fn14 knockout mice, imiquimod psoriasis model, transcriptomic analysis in human keratinocytes, recombinant cytokine stimulation","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific genetic knockout with histological and transcriptomic readouts plus in vitro mechanistic dissection of TWEAK/TNF/IL-17 synergy","pmids":["34797693"],"is_preprint":false},{"year":2024,"finding":"TWEAK secreted by Th17 cells promotes epithelial-mesenchymal transition (EMT) and colorectal cancer liver metastasis by binding Fn14 on tumor cells, activating downstream migration and invasion. CRISPR knockout or siRNA-mediated knockdown of Fn14 in tumor cells reduced metastasis and prolonged survival in mouse models.","method":"CRISPR-Cas9 Fn14 knockout, siRNA knockdown with lipid nanoparticles, mouse metastasis models, single-cell RNA sequencing, Tnfsf12-knockout mice","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic perturbations (CRISPR KO, siRNA, Tnfsf12-KO mice) with in vivo metastasis readouts in a single study","pmids":["38335276"],"is_preprint":false},{"year":2016,"finding":"TWEAK increases SIRT1 expression and promotes p53 deacetylation in activated hepatic stellate cells (LX-2), suppressing cellular senescence (SA-β-Gal activity); Fn14 membrane expression was markedly upregulated by TWEAK, which enhanced cell viability.","method":"Western blotting for SIRT1 and ac-p53, RT-PCR, SA-β-Gal senescence assay, Fn14 expression quantification","journal":"Cell biology international","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single cell line, western blotting and senescence staining without pathway-specific knockdown to confirm mechanism","pmids":["27888541"],"is_preprint":false},{"year":2021,"finding":"TWEAK/Fn14 signaling in Prominin-1-expressing hepatic progenitor cells activates non-canonical NF-κB signaling, driving profibrogenic ductular reactions in biliary atresia. Fn14 antagonism decreased ductular reactions, biliary fibrosis, and periportal fibroblast activation in a mouse model; recombinant TWEAK accelerated murine HPC organoid growth, an effect abolished by Fn14 antagonism.","method":"Fn14 antagonist (L524-0366) in vivo, murine HPC organoid proliferation assay with recombinant TWEAK and antagonist, immunohistochemistry, non-canonical NF-κB pathway western blotting","journal":"Hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological Fn14 blockade in vivo combined with organoid rescue assay, single lab","pmids":["36626628"],"is_preprint":false},{"year":2017,"finding":"TWEAK/Fn14 activation in bullous pemphigoid keratinocytes (HaCaT cells) reduces BP180 expression and cellular adherence via ERK and NF-κB pathway activation and downstream ADAM17 activity; ADAM17 siRNA knockdown preserved BP180 and protected cell adherence.","method":"Fn14 siRNA, ADAM17 siRNA, ERK and NF-κB pathway inhibition, BP180 expression by western blot, cell adherence assay","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown of Fn14 and ADAM17 with functional adherence readout, single lab","pmids":["28351660"],"is_preprint":false},{"year":2024,"finding":"Constitutive Fn14 signaling in TNBC rewires the epigenomic landscape by activating TNBC-specific super-enhancers (via chromatin looping) to transcriptionally upregulate NAMPT, driving NAD+/ATP metabolic reprogramming critical for filopodia formation and metastasis.","method":"Fn14 constitutive expression/knockdown, super-enhancer mapping (H3K27ac ChIP-seq), chromatin looping assay, NAMPT inhibition, metabolomics (NAD+/ATP), filopodia formation assay, in vivo metastasis model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ChIP-seq, chromatin looping, metabolomics, and in vivo models in a single study identifying a mechanistic epigenomic-metabolic axis downstream of Fn14","pmids":["38965263"],"is_preprint":false}],"current_model":"TWEAK (TNFSF12) is a type II transmembrane cytokine that is shed as a biologically active soluble form and signals primarily through its receptor Fn14 (TNFRSF12A), which recruits TRAFs 1, 2, and 3 to activate canonical and non-canonical NF-κB pathways, MAPKs (ERK, JNK, p38), JAK2/STAT3, and PI3K/AKT; TWEAK can also be scavenged by CD163 on macrophages; depending on cellular context and co-stimulatory signals, TWEAK/Fn14 engagement drives proliferation (liver progenitor/oval cells, keratinocytes, myoblast fusion via non-canonical NF-κB), caspase-dependent apoptosis or cathepsin B-dependent necrosis, necroptosis (via RIPK1/RIPK3/MLKL), inflammation (via chemokine/cytokine induction, EGFR transactivation through ADAM17, and HMGB1 upregulation), epigenetic repression of Klotho and PGC-1α through RelA-directed histone deacetylation, and in cancer cells activates super-enhancer-driven NAMPT/NAD+ metabolic reprogramming to promote metastasis."},"narrative":{"mechanistic_narrative":"TNFSF12 (TWEAK) is a type II transmembrane cytokine of the TNF superfamily that is shed as a biologically active soluble ligand and signals through the small TNF-receptor-family member Fn14/TweakR (TNFRSF12A), to which it binds with nanomolar affinity and whose cytoplasmic tail recruits TRAFs 1, 2, and 3 [PMID:11728344, PMID:12787562]. Engagement of Fn14 drives context-dependent outcomes spanning proliferation, cell death, inflammation, and metabolic/epigenetic reprogramming. TWEAK is mitogenic for tissue progenitor cells, expanding liver oval/progenitor cells in an Fn14-dependent manner [PMID:16110324] and promoting hepatic progenitor ductular reactions and myoblast fusion through low-dose activation of the non-canonical NF-κB pathway (NIK/IKKα/p100/RelB) [PMID:23074266, PMID:36626628]. In parallel, TWEAK triggers cell-type-specific death programs—caspase-8/3-dependent apoptosis, cathepsin B-dependent necrosis upon caspase inhibition [PMID:11777967], and an Fn14/RIPK3/MLKL-dependent late wave of necroptosis in injured renal tubules [PMID:29588419]—while an early study showed that in some lines TWEAK-induced apoptosis is relayed indirectly through endogenous TNF/TNFR1 signaling [PMID:10382740]. As a pro-inflammatory effector, TWEAK activates canonical NF-κB, MAPK (ERK/JNK/p38) and AP-1, JAK2/STAT3, and PI3K pathways to induce chemokines, cytokines, HMGB1, endothelin-1/ECE-1, and VEGF, and transactivates EGFR via ADAM17-mediated shedding of HB-EGF/TGFα [PMID:24037740, PMID:23288170, PMID:28411440, PMID:28025386, PMID:19398263], with TRAF3IP2 acting as a causal amplifying intermediate in cardiac fibroblasts [PMID:29981796]. TWEAK also reprograms cellular state by directing RelA-dependent histone deacetylation at the Klotho and PGC-1α promoters to repress these genes and impair mitochondrial function [PMID:21719790, PMID:26535995], and in triple-negative breast cancer drives super-enhancer activation of NAMPT to enable NAD+/ATP metabolic reprogramming and metastasis [PMID:38965263]. Soluble TWEAK can be scavenged by the macrophage receptor CD163, which competes with Fn14 for ligand binding and limits TWEAK-driven tumor cell apoptosis [PMID:17548657]. Pathologically, TWEAK/Fn14 contributes to psoriatic skin inflammation through synergy with TNF and IL-17A [PMID:34797693] and promotes colorectal cancer EMT and liver metastasis when secreted by Th17 cells [PMID:38335276].","teleology":[{"year":1999,"claim":"Established that TWEAK-induced death in some cells is not cell-intrinsic but relayed through endogenous TNF/TNFR1, and that TWEAK acts via a receptor other than the death-domain receptor DR3.","evidence":"Neutralizing antibody and TNFR1-Fc blockade plus RT-PCR for receptor expression in Kym-1 cells","pmids":["10382740"],"confidence":"Medium","gaps":["The non-death-domain TWEAK receptor was undefined at this stage","Did not identify Fn14 as the direct receptor"]},{"year":2001,"claim":"Identified Fn14/TweakR as the high-affinity TWEAK receptor and defined its proximal signaling machinery, resolving the previously undefined receptor and linking TWEAK to angiogenesis and endothelial growth.","evidence":"Receptor cloning, five orthogonal binding assays (Kd ~2.3 nM), TRAF1/2/3 pulldowns, HUVEC proliferation/migration and in vivo corneal angiogenesis","pmids":["11728344"],"confidence":"High","gaps":["Downstream transcriptional outputs not mapped","TRAF-to-NF-κB coupling not yet dissected"]},{"year":2002,"claim":"Showed that TWEAK engages multiple distinct death pathways in a cell-type-specific manner, establishing mechanistic bifurcation between caspase-dependent apoptosis and cathepsin B-dependent necrosis.","evidence":"Caspase activity assays, pharmacological caspase/cathepsin inhibitors, and cathepsin B subcellular fractionation across HSC3 and HT-29 lines","pmids":["11777967"],"confidence":"High","gaps":["Receptor identity confirmed only as non-DR3, not directly Fn14","Molecular switch controlling apoptosis-vs-necrosis not defined"]},{"year":2003,"claim":"Confirmed TWEAK as a type II transmembrane protein shed as an active soluble cytotoxic cytokine acting on Fn14-expressing targets.","evidence":"cDNA transfection, macrophage secretion, cytotoxicity and mAb neutralization assays; review synthesis of cloning/binding data","pmids":["12821115","12787562"],"confidence":"Medium","gaps":["Sheddase responsible for soluble TWEAK generation not identified","Quantitative contribution of membrane vs soluble form unresolved"]},{"year":2005,"claim":"Demonstrated genetically that TWEAK is a selective progenitor-cell mitogen acting through Fn14, establishing a regenerative/proliferative role distinct from its death-inducing activity.","evidence":"Fn14-null and transgenic mice, adenoviral TWEAK, anti-TWEAK mAb, and oval cell proliferation assays","pmids":["16110324"],"confidence":"High","gaps":["Intracellular signaling driving oval cell proliferation not defined here","Selectivity for progenitors over mature hepatocytes mechanistically unexplained"]},{"year":2007,"claim":"Identified CD163 as an alternate scavenger receptor that competes with Fn14 for TWEAK, introducing a ligand-sequestration mechanism that tunes TWEAK availability.","evidence":"Competition binding assays, CHO transfection binding, and monocyte sequestration reversing tumor cell apoptosis","pmids":["17548657"],"confidence":"Medium","gaps":["Physiological significance of CD163 scavenging in vivo not established","Whether CD163 transduces signal or only sequesters unresolved"]},{"year":2011,"claim":"Revealed an epigenetic repressive arm of TWEAK signaling, where RelA directs histone deacetylation at the Klotho promoter to downregulate the gene.","evidence":"ChIP for RelA occupancy and histone deacetylation, NF-κB/HDAC inhibitors, and in vivo TWEAK/anti-TWEAK in tubular cells","pmids":["21719790"],"confidence":"High","gaps":["Specific HDAC recruited not identified","Generality beyond renal tubular cells not tested"]},{"year":2012,"claim":"Defined the non-canonical NF-κB (NIK/IKKα/p100/RelB) pathway as the low-dose TWEAK output controlling myoblast fusion, separating it from canonical NF-κB signaling.","evidence":"Genetic knockdown of p100/RelB/IKKα/NIK, cIAP1 knockout, and multinucleation assays","pmids":["23074266"],"confidence":"High","gaps":["Dose threshold mechanism switching canonical vs non-canonical not molecularly defined","Fusion machinery targets downstream of RelB unidentified"]},{"year":2013,"claim":"Dissected TWEAK-driven inflammation into EGFR-dependent and -independent arms, identifying ADAM17-mediated EGFR ligand shedding as a transactivation route to ERK and proinflammatory genes.","evidence":"Erlotinib and ADAM17 inhibitor treatment in vivo and in vitro with phospho-EGFR/ERK readouts; HMGB1/PI3K-NF-κB dissection in M1 macrophages","pmids":["24037740","23288170"],"confidence":"High","gaps":["Mechanism of Fn14-to-ADAM17 coupling not defined","HMGB1 study (#11) is Medium-confidence single-lab"]},{"year":2016,"claim":"Extended the epigenetic repression model to PGC-1α, linking TWEAK/NF-κB-directed histone deacetylation to mitochondrial dysfunction, and revealed AP-1/NF-κB-driven endothelin induction.","evidence":"ChIP for H3 deacetylation at PGC-1α promoter, PGC-1α rescue, mitochondrial membrane potential; ECE-1 promoter mapping and EMSA for the endothelin axis","pmids":["26535995","28025386"],"confidence":"High","gaps":["Endothelin/SIRT1 findings vary in confidence and tissue","Connection between mitochondrial repression and cell fate not established"]},{"year":2018,"claim":"Established TWEAK/Fn14 as a driver of RIPK1/RIPK3/MLKL-dependent necroptosis and of TRAF3IP2-amplified pro-fibrotic and JAK2/STAT3-hypertrophic responses, broadening the cell-fate and tissue-remodeling repertoire.","evidence":"RIPK3/MLKL/Fn14 knockouts and necrostatin-1 in AKI; TRAF3IP2 KO/siLNA in cardiac fibroblasts; JAK2/STAT3/Fn14 siRNA in atrial myocytes","pmids":["29588419","29981796","29971943"],"confidence":"High","gaps":["What dictates necroptosis vs apoptosis timing in tissue not fully resolved","TRAF3IP2 positive-feedback initiation trigger unknown"]},{"year":2021,"claim":"Demonstrated cell-type-specific, genetically defined roles for Fn14 in epithelial pathology—keratinocyte-driven psoriatic inflammation via TWEAK/TNF/IL-17A synergy and hepatic progenitor non-canonical NF-κB-driven biliary fibrosis.","evidence":"Keratinocyte-specific Fn14 KO in imiquimod model with keratinocyte transcriptomics; Fn14 antagonist and HPC organoid rescue in biliary atresia model","pmids":["34797693","36626628"],"confidence":"High","gaps":["Molecular basis of TWEAK/TNF/IL-17 transcriptional synergy not fully mapped","Progenitor-specific signaling components incompletely defined"]},{"year":2024,"claim":"Uncovered an oncogenic epigenomic-metabolic axis in which Fn14 activates super-enhancers to upregulate NAMPT-driven NAD+/ATP metabolism enabling metastasis, and showed Th17-derived TWEAK drives EMT and colorectal liver metastasis.","evidence":"H3K27ac ChIP-seq, chromatin looping, NAMPT inhibition and metabolomics in TNBC; CRISPR/siRNA Fn14 KO and Tnfsf12-KO mice in CRC metastasis models","pmids":["38965263","38335276"],"confidence":"High","gaps":["How Fn14 signaling reaches super-enhancer machinery not mechanistically resolved","Therapeutic targetability of the TWEAK-NAMPT axis untested clinically"]},{"year":null,"claim":"How a single TWEAK/Fn14 axis selects among proliferation, apoptosis, necroptosis, inflammation, and epigenetic/metabolic reprogramming—and what molecular thresholds (ligand dose, cIAP/TRAF state, co-stimulatory context) govern the switch—remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking receptor occupancy to fate choice","Sheddase generating soluble TWEAK and its regulation undefined","In vivo balance between Fn14 signaling and CD163 scavenging unquantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,17,18]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3,6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[17,18]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[17,18]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,6,7,12]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2,9]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11,12,19]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[5,8,24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[20,24]}],"complexes":[],"partners":["TNFRSF12A","CD163","TRAF1","TRAF2","TRAF3","TRAF3IP2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O43508","full_name":"Tumor necrosis factor ligand superfamily member 12","aliases":["APO3 ligand","TNF-related weak inducer of apoptosis","TWEAK"],"length_aa":249,"mass_kda":27.2,"function":"Binds to FN14 and possibly also to TNRFSF12/APO3. Weak inducer of apoptosis in some cell types. Mediates NF-kappa-B activation. Promotes angiogenesis and the proliferation of endothelial cells. Also involved in induction of inflammatory cytokines. Promotes IL8 secretion","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/O43508/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFSF12","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFSF12","total_profiled":1310},"omim":[{"mim_id":"608464","title":"ANGIOGENIC FACTOR WITH G-PATCH AND FHA DOMAINS 1; AGGF1","url":"https://www.omim.org/entry/608464"},{"mim_id":"605914","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 12A; TNFRSF12A","url":"https://www.omim.org/entry/605914"},{"mim_id":"604472","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 13; TNFSF13","url":"https://www.omim.org/entry/604472"},{"mim_id":"603366","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 25; TNFRSF25","url":"https://www.omim.org/entry/603366"},{"mim_id":"602695","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 12; TNFSF12","url":"https://www.omim.org/entry/602695"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TNFSF12"},"hgnc":{"alias_symbol":["TWEAK","DR3LG","APO3L","TNF12"],"prev_symbol":[]},"alphafold":{"accession":"O43508","domains":[{"cath_id":"2.60.120.40","chopping":"108-246","consensus_level":"high","plddt":93.2414,"start":108,"end":246}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O43508","model_url":"https://alphafold.ebi.ac.uk/files/AF-O43508-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O43508-F1-predicted_aligned_error_v6.png","plddt_mean":77.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFSF12","jax_strain_url":"https://www.jax.org/strain/search?query=TNFSF12"},"sequence":{"accession":"O43508","fasta_url":"https://rest.uniprot.org/uniprotkb/O43508.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O43508/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O43508"}},"corpus_meta":[{"pmid":"18404150","id":"PMC_18404150","title":"The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting.","date":"2008","source":"Nature reviews. Drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/18404150","citation_count":499,"is_preprint":false},{"pmid":"21719790","id":"PMC_21719790","title":"The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB.","date":"2011","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/21719790","citation_count":347,"is_preprint":false},{"pmid":"16110324","id":"PMC_16110324","title":"TWEAK induces liver progenitor cell proliferation.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16110324","citation_count":336,"is_preprint":false},{"pmid":"11728344","id":"PMC_11728344","title":"A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis.","date":"2001","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11728344","citation_count":330,"is_preprint":false},{"pmid":"12787562","id":"PMC_12787562","title":"TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor.","date":"2003","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12787562","citation_count":254,"is_preprint":false},{"pmid":"17981048","id":"PMC_17981048","title":"TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease.","date":"2007","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/17981048","citation_count":246,"is_preprint":false},{"pmid":"17548657","id":"PMC_17548657","title":"A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17548657","citation_count":197,"is_preprint":false},{"pmid":"22017434","id":"PMC_22017434","title":"TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses.","date":"2011","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22017434","citation_count":182,"is_preprint":false},{"pmid":"11777967","id":"PMC_11777967","title":"Multiple pathways of TWEAK-induced cell death.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11777967","citation_count":149,"is_preprint":false},{"pmid":"10382740","id":"PMC_10382740","title":"TWEAK can induce cell death via endogenous TNF and TNF receptor 1.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10382740","citation_count":140,"is_preprint":false},{"pmid":"29588419","id":"PMC_29588419","title":"TWEAK and RIPK1 mediate a second wave of cell death during AKI.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29588419","citation_count":132,"is_preprint":false},{"pmid":"16888023","id":"PMC_16888023","title":"TWEAK is a novel arthritogenic mediator.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16888023","citation_count":132,"is_preprint":false},{"pmid":"15056843","id":"PMC_15056843","title":"TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages.","date":"2004","source":"Circulation journal : official journal of the Japanese Circulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/15056843","citation_count":123,"is_preprint":false},{"pmid":"26535995","id":"PMC_26535995","title":"The inflammatory cytokine TWEAK decreases PGC-1α expression and mitochondrial function in acute kidney injury.","date":"2016","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/26535995","citation_count":118,"is_preprint":false},{"pmid":"15353286","id":"PMC_15353286","title":"The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity.","date":"2004","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/15353286","citation_count":97,"is_preprint":false},{"pmid":"21697814","id":"PMC_21697814","title":"TWEAK, a multifunctional cytokine in kidney injury.","date":"2011","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/21697814","citation_count":97,"is_preprint":false},{"pmid":"22727560","id":"PMC_22727560","title":"Role of TWEAK in lupus nephritis: a bench-to-bedside review.","date":"2012","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/22727560","citation_count":95,"is_preprint":false},{"pmid":"24493870","id":"PMC_24493870","title":"TWEAK and the progression of renal disease: clinical translation.","date":"2014","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/24493870","citation_count":92,"is_preprint":false},{"pmid":"28619231","id":"PMC_28619231","title":"Endoplasmic reticulum chaperones tweak the mitochondrial calcium rheostat to control metabolism and cell death.","date":"2017","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/28619231","citation_count":87,"is_preprint":false},{"pmid":"28809783","id":"PMC_28809783","title":"Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in Obesity and Diabetes Development.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28809783","citation_count":85,"is_preprint":false},{"pmid":"22366923","id":"PMC_22366923","title":"TWEAK and TRAF6 regulate skeletal muscle atrophy.","date":"2012","source":"Current opinion in clinical nutrition and metabolic care","url":"https://pubmed.ncbi.nlm.nih.gov/22366923","citation_count":84,"is_preprint":false},{"pmid":"24400009","id":"PMC_24400009","title":"Neuropsychiatric Lupus, the Blood Brain Barrier, and the TWEAK/Fn14 Pathway.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24400009","citation_count":80,"is_preprint":false},{"pmid":"34797693","id":"PMC_34797693","title":"TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy.","date":"2021","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34797693","citation_count":79,"is_preprint":false},{"pmid":"24636536","id":"PMC_24636536","title":"TWEAK/Fn14 axis: the current paradigm of tissue injury-inducible function in the midst of complexities.","date":"2014","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24636536","citation_count":79,"is_preprint":false},{"pmid":"23957828","id":"PMC_23957828","title":"The TWEAK-Fn14 system as a potential drug target.","date":"2013","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23957828","citation_count":78,"is_preprint":false},{"pmid":"23074266","id":"PMC_23074266","title":"TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-κB signaling pathway.","date":"2012","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/23074266","citation_count":71,"is_preprint":false},{"pmid":"28530223","id":"PMC_28530223","title":"TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28530223","citation_count":70,"is_preprint":false},{"pmid":"23320797","id":"PMC_23320797","title":"TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier.","date":"2013","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/23320797","citation_count":67,"is_preprint":false},{"pmid":"26300004","id":"PMC_26300004","title":"The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26300004","citation_count":63,"is_preprint":false},{"pmid":"38335276","id":"PMC_38335276","title":"Th17 Cells Secrete TWEAK to Trigger Epithelial-Mesenchymal Transition and Promote Colorectal Cancer Liver Metastasis.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38335276","citation_count":61,"is_preprint":false},{"pmid":"24478772","id":"PMC_24478772","title":"TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24478772","citation_count":61,"is_preprint":false},{"pmid":"24478779","id":"PMC_24478779","title":"TWEAK/Fn14 Signaling Axis Mediates Skeletal Muscle Atrophy and Metabolic Dysfunction.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24478779","citation_count":60,"is_preprint":false},{"pmid":"33221352","id":"PMC_33221352","title":"TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression.","date":"2020","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/33221352","citation_count":58,"is_preprint":false},{"pmid":"34542797","id":"PMC_34542797","title":"The TWEAK/Fn14/CD163 axis-implications for metabolic disease.","date":"2021","source":"Reviews in endocrine & metabolic disorders","url":"https://pubmed.ncbi.nlm.nih.gov/34542797","citation_count":58,"is_preprint":false},{"pmid":"24444596","id":"PMC_24444596","title":"The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease.","date":"2013","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/24444596","citation_count":58,"is_preprint":false},{"pmid":"18483204","id":"PMC_18483204","title":"No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies.","date":"2008","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/18483204","citation_count":58,"is_preprint":false},{"pmid":"28639899","id":"PMC_28639899","title":"TWEAK/Fn14 signaling in tumors.","date":"2017","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28639899","citation_count":57,"is_preprint":false},{"pmid":"15885893","id":"PMC_15885893","title":"TWEAK and Fn14: new molecular targets for cancer therapy?","date":"2006","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15885893","citation_count":57,"is_preprint":false},{"pmid":"22672874","id":"PMC_22672874","title":"The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases.","date":"2012","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/22672874","citation_count":57,"is_preprint":false},{"pmid":"29038621","id":"PMC_29038621","title":"TWEAK/Fn14 Activation Participates in Skin Inflammation.","date":"2017","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/29038621","citation_count":54,"is_preprint":false},{"pmid":"19482507","id":"PMC_19482507","title":"Considering TWEAK as a target for therapy in renal and vascular injury.","date":"2009","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19482507","citation_count":53,"is_preprint":false},{"pmid":"30014744","id":"PMC_30014744","title":"miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT pathway and predicts favorable survival in human osteosarcoma.","date":"2018","source":"International journal of immunopathology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30014744","citation_count":52,"is_preprint":false},{"pmid":"24339827","id":"PMC_24339827","title":"TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24339827","citation_count":51,"is_preprint":false},{"pmid":"12821115","id":"PMC_12821115","title":"Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12821115","citation_count":51,"is_preprint":false},{"pmid":"18793781","id":"PMC_18793781","title":"Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke.","date":"2008","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18793781","citation_count":51,"is_preprint":false},{"pmid":"19018248","id":"PMC_19018248","title":"Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury.","date":"2008","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19018248","citation_count":51,"is_preprint":false},{"pmid":"30010468","id":"PMC_30010468","title":"The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC.","date":"2018","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/30010468","citation_count":50,"is_preprint":false},{"pmid":"33705829","id":"PMC_33705829","title":"Cross-talk between IFN-γ and TWEAK through miR-149 amplifies skin inflammation in psoriasis.","date":"2021","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33705829","citation_count":50,"is_preprint":false},{"pmid":"19398263","id":"PMC_19398263","title":"TWEAK promotes ovarian cancer cell metastasis via NF-kappaB pathway activation and VEGF expression.","date":"2009","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/19398263","citation_count":50,"is_preprint":false},{"pmid":"17127278","id":"PMC_17127278","title":"Role of TWEAK and Fn14 in tumor biology.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17127278","citation_count":48,"is_preprint":false},{"pmid":"24970477","id":"PMC_24970477","title":"AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24970477","citation_count":48,"is_preprint":false},{"pmid":"24037740","id":"PMC_24037740","title":"TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation.","date":"2013","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24037740","citation_count":47,"is_preprint":false},{"pmid":"33000480","id":"PMC_33000480","title":"TWEAK/Fn14 axis is an important player in fibrosis.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33000480","citation_count":45,"is_preprint":false},{"pmid":"17485328","id":"PMC_17485328","title":"TWEAK and Fn14. New players in the pathogenesis of atherosclerosis.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17485328","citation_count":45,"is_preprint":false},{"pmid":"24550918","id":"PMC_24550918","title":"Role of the TWEAK-Fn14-cIAP1-NF-κB Signaling Axis in the Regulation of Myogenesis and Muscle Homeostasis.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24550918","citation_count":45,"is_preprint":false},{"pmid":"16503147","id":"PMC_16503147","title":"Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity.","date":"2006","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/16503147","citation_count":45,"is_preprint":false},{"pmid":"28351660","id":"PMC_28351660","title":"TWEAK/Fn14 Activation Contributes to the Pathogenesis of Bullous Pemphigoid.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28351660","citation_count":43,"is_preprint":false},{"pmid":"17917114","id":"PMC_17917114","title":"TWEAK and the central nervous system.","date":"2007","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/17917114","citation_count":42,"is_preprint":false},{"pmid":"26264384","id":"PMC_26264384","title":"TWEAK/Fn14 activation induces keratinocyte proliferation under psoriatic inflammation.","date":"2015","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/26264384","citation_count":41,"is_preprint":false},{"pmid":"28411440","id":"PMC_28411440","title":"TWEAK/Fn14 promotes pro-inflammatory cytokine secretion in hepatic stellate cells via NF-κB/STAT3 pathways.","date":"2017","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28411440","citation_count":41,"is_preprint":false},{"pmid":"21435232","id":"PMC_21435232","title":"TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis.","date":"2011","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21435232","citation_count":40,"is_preprint":false},{"pmid":"22819243","id":"PMC_22819243","title":"TWEAK promotes the production of Interleukin-17 in rheumatoid arthritis.","date":"2012","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/22819243","citation_count":40,"is_preprint":false},{"pmid":"24416031","id":"PMC_24416031","title":"TWEAK: A New Player in Obesity and Diabetes.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24416031","citation_count":39,"is_preprint":false},{"pmid":"15586228","id":"PMC_15586228","title":"Functional expression of TWEAK in human colonic adenocarcinoma cells.","date":"2005","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15586228","citation_count":38,"is_preprint":false},{"pmid":"22082477","id":"PMC_22082477","title":"The TWEAK-Fn14 system: breaking the silence of cytokine-induced skeletal muscle wasting.","date":"2012","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22082477","citation_count":38,"is_preprint":false},{"pmid":"24479820","id":"PMC_24479820","title":"Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice.","date":"2014","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24479820","citation_count":37,"is_preprint":false},{"pmid":"29981796","id":"PMC_29981796","title":"TRAF3IP2 mediates TWEAK/TWEAKR-induced pro-fibrotic responses in cultured cardiac fibroblasts and the heart.","date":"2018","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/29981796","citation_count":36,"is_preprint":false},{"pmid":"30081003","id":"PMC_30081003","title":"TWEAK/Fn14 Signals Mediate Burn Wound Repair.","date":"2018","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30081003","citation_count":35,"is_preprint":false},{"pmid":"26659091","id":"PMC_26659091","title":"Role of the TWEAK/Fn14 pathway in autoimmune diseases.","date":"2016","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/26659091","citation_count":35,"is_preprint":false},{"pmid":"24611063","id":"PMC_24611063","title":"TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24611063","citation_count":35,"is_preprint":false},{"pmid":"23288170","id":"PMC_23288170","title":"HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes.","date":"2013","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23288170","citation_count":35,"is_preprint":false},{"pmid":"34155062","id":"PMC_34155062","title":"TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.","date":"2021","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/34155062","citation_count":34,"is_preprint":false},{"pmid":"29456665","id":"PMC_29456665","title":"Involvement of TWEAK and the NF-κB signaling pathway in lupus nephritis.","date":"2018","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29456665","citation_count":34,"is_preprint":false},{"pmid":"24409182","id":"PMC_24409182","title":"Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases?","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24409182","citation_count":34,"is_preprint":false},{"pmid":"25504044","id":"PMC_25504044","title":"TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25504044","citation_count":33,"is_preprint":false},{"pmid":"32526219","id":"PMC_32526219","title":"TWEAK/Fn14 axis in respiratory diseases.","date":"2020","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32526219","citation_count":31,"is_preprint":false},{"pmid":"27339384","id":"PMC_27339384","title":"Out of the TWEAKlight: Elucidating the Role of Fn14 and TWEAK in Acute Kidney Injury.","date":"2016","source":"Seminars in nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/27339384","citation_count":30,"is_preprint":false},{"pmid":"24376672","id":"PMC_24376672","title":"BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 proteins are related to human glioma tumor grade: immunohistochemistry and public microarray data meta-analysis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24376672","citation_count":30,"is_preprint":false},{"pmid":"19513634","id":"PMC_19513634","title":"Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway.","date":"2009","source":"Results and problems in cell differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/19513634","citation_count":29,"is_preprint":false},{"pmid":"14555217","id":"PMC_14555217","title":"TWE-PRIL; a fusion protein of TWEAK and APRIL.","date":"2003","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14555217","citation_count":28,"is_preprint":false},{"pmid":"32200423","id":"PMC_32200423","title":"Controversies in TWEAK-Fn14 signaling in skeletal muscle atrophy and regeneration.","date":"2020","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/32200423","citation_count":27,"is_preprint":false},{"pmid":"24408972","id":"PMC_24408972","title":"TWEAK/Fn14 pathway is a novel mediator of retinal neovascularization.","date":"2014","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/24408972","citation_count":27,"is_preprint":false},{"pmid":"26499979","id":"PMC_26499979","title":"Serum levels of TWEAK in patients with psoriasis vulgaris.","date":"2015","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/26499979","citation_count":27,"is_preprint":false},{"pmid":"24273541","id":"PMC_24273541","title":"TWEAK and Fn14 in the Neurovascular Unit.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24273541","citation_count":26,"is_preprint":false},{"pmid":"29971943","id":"PMC_29971943","title":"TWEAK/Fn14 mediates atrial-derived HL-1 myocytes hypertrophy via JAK2/STAT3 signalling pathway.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29971943","citation_count":26,"is_preprint":false},{"pmid":"23469193","id":"PMC_23469193","title":"Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23469193","citation_count":26,"is_preprint":false},{"pmid":"33512736","id":"PMC_33512736","title":"TWEAK-Fn14 as a common pathway in the heart and the kidneys in cardiorenal syndrome.","date":"2021","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33512736","citation_count":25,"is_preprint":false},{"pmid":"31051431","id":"PMC_31051431","title":"VPS29, a tweak tool of endosomal recycling.","date":"2019","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31051431","citation_count":25,"is_preprint":false},{"pmid":"15850771","id":"PMC_15850771","title":"TWEAK mediates anti-tumor effect of tumor-infiltrating macrophage.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15850771","citation_count":25,"is_preprint":false},{"pmid":"24406502","id":"PMC_24406502","title":"Nrf2 protects against TWEAK-mediated skeletal muscle wasting.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24406502","citation_count":25,"is_preprint":false},{"pmid":"36626628","id":"PMC_36626628","title":"TWEAK/FN14 promotes profibrogenic pathway activation in Prominin-1-expressing hepatic progenitor cells in biliary atresia.","date":"2023","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/36626628","citation_count":24,"is_preprint":false},{"pmid":"31097613","id":"PMC_31097613","title":"TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?","date":"2019","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/31097613","citation_count":24,"is_preprint":false},{"pmid":"17485258","id":"PMC_17485258","title":"Tweak and FN14 in central nervous system health and disease.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17485258","citation_count":23,"is_preprint":false},{"pmid":"28025386","id":"PMC_28025386","title":"Tweak up-regulates endothelin-1 system in mouse and human endothelial cells.","date":"2016","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/28025386","citation_count":22,"is_preprint":false},{"pmid":"23443741","id":"PMC_23443741","title":"Expression of TWEAK/Fn14 in neuroblastoma: implications in tumorigenesis.","date":"2013","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23443741","citation_count":22,"is_preprint":false},{"pmid":"38965263","id":"PMC_38965263","title":"TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38965263","citation_count":21,"is_preprint":false},{"pmid":"34246833","id":"PMC_34246833","title":"Bacterial effectors mimicking ubiquitin-proteasome pathway tweak plant immunity.","date":"2021","source":"Microbiological research","url":"https://pubmed.ncbi.nlm.nih.gov/34246833","citation_count":21,"is_preprint":false},{"pmid":"30414907","id":"PMC_30414907","title":"TWEAK/Fn14 Interaction Confers Aggressive Properties to Cutaneous Squamous Cell Carcinoma.","date":"2018","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30414907","citation_count":20,"is_preprint":false},{"pmid":"27888541","id":"PMC_27888541","title":"TWEAK increases SIRT1 expression and promotes p53 deacetylation affecting human hepatic stellate cell senescence.","date":"2016","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/27888541","citation_count":20,"is_preprint":false},{"pmid":"29266762","id":"PMC_29266762","title":"The TWEAK/Fn14 pathway is required for calcineurin inhibitor toxicity of the kidneys.","date":"2018","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/29266762","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48224,"output_tokens":7199,"usd":0.126329,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16514,"output_tokens":5132,"usd":0.105435,"stage2_stop_reason":"end_turn"},"total_usd":0.231764,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"TWEAK binds a novel TNF receptor superfamily member (TweakR/Fn14) cloned from a human umbilical vein endothelial cell library; the interaction has an affinity constant (Kd) of 2.3 ± 0.1 nM as measured by five independent binding assays. The TweakR cytoplasmic domain binds TRAFs 1, 2, and 3. Cross-linking of TweakR induces HUVEC growth, and soluble TweakR inhibits endothelial cell migration in vitro and corneal angiogenesis in vivo.\",\n      \"method\": \"Receptor cloning, five binding assays, TRAF pulldown/binding assays, HUVEC proliferation and migration assays, in vivo corneal angiogenesis model\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — receptor cloning with multiple orthogonal binding assays, TRAF interaction, functional in vitro and in vivo validation in a single rigorous study\",\n      \"pmids\": [\"11728344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TWEAK-induced apoptosis in Kym-1 cells is indirect, mediated by endogenous TNF signaling through TNFR1; TNFR1-Fc fusion protein, neutralizing anti-TNF antibodies, and TNFR1-specific Fab fragments each blocked cell death. TWEAK also co-stimulates TNFR1-mediated cell death. Kym-1 cells do not express DR3/APO3 at protein or mRNA level, indicating a separate, undefined non-death-domain TWEAK receptor.\",\n      \"method\": \"Neutralizing antibody blockade, TNFR1-Fc fusion protein, flow cytometry binding assay, RT-PCR for receptor expression\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal blocking approaches in a single study establishing indirect TNF-mediated mechanism\",\n      \"pmids\": [\"10382740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TWEAK induces multiple cell-death pathways in a cell-type-specific manner: (1) caspase-8 and caspase-3 dependent apoptosis in HSC3 cells; (2) cathepsin B-dependent necrosis in IFN-γ-treated HT-29 cells, accompanied by cytosolic release of cathepsin B from lysosomes. Pan-caspase inhibition switches HT-29 death to necrosis. None of the TWEAK-sensitive lines express DR3, confirming TWEAK acts through a receptor distinct from DR3.\",\n      \"method\": \"Caspase activity assays, caspase and lysosomal proteinase inhibitors, cathepsin B subcellular fractionation, flow cytometry receptor binding, RT-PCR and western for DR3\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple cell lines, enzymatic activity assays with pharmacological inhibitors, and subcellular fractionation identifying mechanistic bifurcation\",\n      \"pmids\": [\"11777967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TWEAK selectively stimulates proliferation of liver oval (progenitor) cells but has no mitogenic effect on mature hepatocytes. This mitogenic activity is mediated through the Fn14 receptor: TWEAK-expressing adenovirus induces oval cell expansion in wild-type but not Fn14-null mice, and a blocking anti-TWEAK mAb reduces DDC-induced oval cell expansion.\",\n      \"method\": \"Transgenic mouse overexpression, Fn14-null mouse genetic model, adenoviral TWEAK delivery, anti-TWEAK blocking mAb, oval cell culture proliferation assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic (Fn14-KO) and antibody blocking approaches combined with in vitro proliferation assay, replicated across multiple experimental models\",\n      \"pmids\": [\"16110324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CD163, a scavenger receptor on monocytes/macrophages, binds TWEAK with dose-dependent affinity. In competition assays, soluble CD163 and Fn14 competitively displace TWEAK from their respective coated binding partners. Monocytes (Fn14-negative, CD163-positive) can sequester TWEAK from supernatants, preventing tumor cell apoptosis; this was reversed by an anti-CD163 mAb or a CD163-mimicking peptide. Recombinant TWEAK binding to CD163-transfected CHO cells was inhibited by unlabeled TWEAK or Hp-Hb complex.\",\n      \"method\": \"Combinatorial peptide library screen, dose-dependent binding assay, competition binding assay, flow cytometry, immunofluorescence, CHO cell transfection binding assay, functional apoptosis assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal binding and functional assays in a single study establishing CD163 as an alternate TWEAK-binding protein\",\n      \"pmids\": [\"17548657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TWEAK and TNFα reduce renal Klotho expression through an NF-κB-dependent mechanism: TWEAK activates NF-κB and promotes RelA binding to the Klotho promoter with accompanying histone deacetylation, as shown by chromatin immunoprecipitation. NF-κB inhibition with parthenolide and HDAC inhibitor treatment each reversed TWEAK-induced Klotho downregulation.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), siRNA knockdown of IκBα, NF-κB and HDAC inhibitor pharmacology, in vivo TWEAK administration with TWEAK blockade/KO, tubular cell culture\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP directly demonstrating RelA occupancy at Klotho promoter plus histone modification, corroborated by in vivo genetic and pharmacological approaches\",\n      \"pmids\": [\"21719790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TWEAK at low concentrations preferentially activates the non-canonical NF-κB pathway and increases myoblast fusion. Loss of cIAP1 constitutively activates non-canonical NF-κB and amplifies fusion; knockdown of p100, RelB, IKKα, or NIK attenuates fusion in wild-type myoblasts, placing non-canonical NF-κB signaling downstream of TWEAK-Fn14 in the regulation of myoblast fusion.\",\n      \"method\": \"Genetic knockdown (siRNA), cIAP1 knockout cells, p52/RelB overexpression, TRAF3 depletion, NF-κB pathway component manipulation, multinucleation counting assay\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — epistasis established by multiple genetic perturbations and rescue experiments in a single rigorous study\",\n      \"pmids\": [\"23074266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TWEAK transactivates the EGFR in renal tubular cells via Fn14 binding, leading to ADAM17 activation and release of EGFR ligands HB-EGF and TGFα. EGFR transactivation drives ERK activation and proinflammatory gene upregulation, while NF-κB activation is EGFR-independent. In vivo, erlotinib (EGFR kinase inhibitor) and WTACE-2 (ADAM17 inhibitor) blocked TWEAK-induced renal EGFR phosphorylation and inflammation.\",\n      \"method\": \"In vivo TWEAK administration with erlotinib or ADAM17 inhibitor treatment, in vitro kinase inhibitor assays, western blotting for phospho-EGFR/ERK, anti-EGFR/ADAM17/ERK inhibitors\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mechanistic pathway dissection with multiple inhibitors in both in vitro and in vivo systems, identifying ADAM17 as the transactivation intermediate\",\n      \"pmids\": [\"24037740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TWEAK decreases PGC-1α expression and mitochondrial function in renal tubular cells through an NF-κB-dependent mechanism involving histone H3 deacetylation at the PGC-1α promoter. Adenoviral PGC-1α overexpression prevents TWEAK-induced mitochondrial membrane potential loss. NF-κB or HDAC inhibitors prevented TWEAK-induced PGC-1α downregulation.\",\n      \"method\": \"Chromatin immunoprecipitation (H3 deacetylation at PGC-1α promoter), adenoviral PGC-1α overexpression rescue, NF-κB and HDAC pharmacological inhibitors, in vivo anti-TWEAK antibody treatment, mitochondrial membrane potential measurement\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP demonstrating epigenetic modification at PGC-1α promoter plus rescue by PGC-1α overexpression and pathway inhibition, validated in vivo\",\n      \"pmids\": [\"26535995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TWEAK/Fn14 activation drives a second wave of necroptosis in acute kidney injury (AKI) at 72–96 h: TWEAK induces apoptosis in a proinflammatory environment in tubular cells, but caspase inhibition switches death to necroptosis. Genetic deficiency of RIPK3, MLKL, or Fn14, or treatment with necrostatin-1 (RIPK1 inhibitor), prevented late-phase cell death and renal dysfunction but not early injury (48 h).\",\n      \"method\": \"Genetic knockouts (RIPK3-KO, Fn14-KO), MLKL deficiency, necrostatin-1 pharmacology, folic acid-induced AKI mouse model, in vitro tubular cell death assays with caspase inhibition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models plus pharmacological corroboration establishing TWEAK/Fn14-RIPK1 necroptosis axis with defined temporal window\",\n      \"pmids\": [\"29588419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TRAF3IP2 mediates TWEAK/TWEAKR-induced pro-fibrotic responses in cardiac fibroblasts: forced TRAF3IP2 expression upregulates TWEAK and TWEAKR; exogenous TWEAK upregulates TRAF3IP2 in a dose/time-dependent manner (positive feedback). TRAF3IP2 silencing inhibits TWEAK-induced p38 MAPK, NF-κB and AP-1 activation, inflammatory cytokine expression, MMP/TIMP1, collagen secretion, and fibroblast proliferation/migration. TWEAK infusion in vivo induces cardiac TRAF3IP2, NF-κB/AP-1, fibrosis and dysfunction; genetic TRAF3IP2 ablation prevents these changes.\",\n      \"method\": \"siRNA silencing, forced expression, western blotting, in vivo TWEAK infusion with TRAF3IP2 knockout mice, collagen secretion assay, migration assay\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic (KO) and siRNA approaches in vitro and in vivo, multiple orthogonal readouts establishing TRAF3IP2 as a causal signaling intermediate\",\n      \"pmids\": [\"29981796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TWEAK increases HMGB1 mRNA expression and protein secretion in monocyte/macrophage (THP-1) cells via Fn14 binding and NF-κB and PI3K pathway activation; this effect is restricted to M1 macrophages and not M2. TWEAK-induced HMGB1 in turn promotes MCP-1 secretion (blocked by HMGB1 siRNA). In vivo, systemic TWEAK injection in ApoE-/- mice elevated aortic HMGB1; anti-TWEAK antibodies reduced it.\",\n      \"method\": \"Blocking anti-Fn14 antibody, NF-κB and PI3K pharmacological inhibitors, HMGB1 siRNA, in vivo TWEAK injection and anti-TWEAK antibody treatment in ApoE-/- mice, ELISA, qPCR\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple inhibitors and siRNA knockdown in vitro with in vivo corroboration, single lab study\",\n      \"pmids\": [\"23288170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TWEAK promotes pro-inflammatory cytokine secretion (IL-8, IL-6, RANTES, MCP-1) in activated hepatic stellate cells (LX-2) via concurrent NF-κB and STAT3 pathway activation; STAT3 and NF-κB interact with each other, and siRNA knockdown of either pathway component reduces cytokine output synergistically.\",\n      \"method\": \"siRNA knockdown of NF-κB and JAK2/STAT3 components, western blotting for phosphorylated signaling proteins, ELISA for cytokines, RT-PCR\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown of two parallel pathways with multiple cytokine readouts, single lab\",\n      \"pmids\": [\"28411440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TWEAK upregulates endothelin-converting enzyme-1 (ECE-1) and endothelin-1 (ET-1) in endothelial cells via AP-1 (ERK1/2 and JNK pathways) and NF-κB transcriptional activation, demonstrated by ECE-1 promoter serial deletion assays, EMSA for AP-1/NF-κB binding, and pharmacological inhibitors of ERK1/2 (PD-98059), JNK (SP-600125), and NF-κB (PDTC). In vivo TWEAK administration elevated ET-1 and ECE-1 in mouse aorta/lung and induced transient hypertension.\",\n      \"method\": \"ECE-1 promoter deletion/transfection assays, EMSA, ERK/JNK/NF-κB pharmacological inhibitors, in vivo TWEAK injection, ELISA, qPCR, western blotting\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — promoter deletion mapping and EMSA mechanistically identify AP-1/NF-κB sites, corroborated in vivo, single lab\",\n      \"pmids\": [\"28025386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TWEAK promotes ovarian cancer cell migration, invasion, and VEGF upregulation via NF-κB pathway activation: TWEAK treatment causes NF-κB nuclear translocation, and NF-κB inhibition (PDTC) suppresses TWEAK-induced VEGF expression and metastatic behavior in HO-8910PM cells.\",\n      \"method\": \"NF-κB nuclear translocation assay, NF-κB pharmacological inhibition (PDTC), VEGF protein measurement, migration/invasion assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with multiple functional readouts, single lab\",\n      \"pmids\": [\"19398263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TWEAK/Fn14 activation promotes atrial myocyte hypertrophy (HL-1 cells) via JAK2/STAT3 signaling: TWEAK increased ANP and Troponin T expression and cell size; siRNA knockdown of JAK2 or STAT3 attenuated TWEAK-induced hypertrophy; Fn14 knockdown counteracted TWEAK effects.\",\n      \"method\": \"siRNA knockdown of JAK2, STAT3, and Fn14; western blotting for ANP and Troponin T; cell size measurement\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA epistasis of JAK2/STAT3 with multiple readouts, single lab, in vitro\",\n      \"pmids\": [\"29971943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TWEAK induces RANKL surface expression on immature STRO-1+ human osteoblasts, providing a mechanism for TWEAK-mediated bone erosion in rheumatoid arthritis. Soluble TWEAK did not directly stimulate osteoclast formation from PBMCs (negative result for direct osteoclastogenesis).\",\n      \"method\": \"Flow cytometry for surface RANKL on osteoblasts, PBMC osteoclastogenesis assay with sTWEAK, immunohistochemistry for TWEAK/Fn14 in RA synovium\",\n      \"journal\": \"Arthritis research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assay on primary human osteoblasts establishing RANKL induction; negative result for direct osteoclastogenesis explicitly noted; single lab\",\n      \"pmids\": [\"21435232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Murine TWEAK is expressed as a functional cell-surface protein on TWEAK-transfected cells and is secreted by thioglycolate-elicited peritoneal macrophages; the secreted form is cytotoxic against Fn14-expressing target cells and is neutralized by an anti-murine TWEAK mAb (MTW-1).\",\n      \"method\": \"cDNA transfection, anti-TWEAK and anti-Fn14 mAb generation, flow cytometry, cytotoxicity assay, neutralization assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct demonstration of secretion and cytotoxic activity with mAb neutralization, single lab\",\n      \"pmids\": [\"12821115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TWEAK is identified as a type II transmembrane protein that can be shed as a biologically active soluble form. Its only known signaling receptor is Fn14/TweakR, the smallest TNFR superfamily member, which signals via TRAF recruitment.\",\n      \"method\": \"Literature synthesis of cloning studies and binding characterization\",\n      \"journal\": \"Cytokine & growth factor reviews\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Strong — review summarizing prior experimental identification data; cited as a synthesis of established experimental findings from multiple labs\",\n      \"pmids\": [\"12787562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In psoriasis, TWEAK strongly synergizes with TNF and IL-17A to upregulate psoriasis-associated genes (IL23A, IL36G, CXC chemokines) in human keratinocytes. Fn14 (TNFRSF12A), the TWEAK receptor, is expressed in keratinocytes; keratinocyte-specific deletion of Fn14 reduced imiquimod-induced skin inflammation and epidermal hyperplasia in mice.\",\n      \"method\": \"Keratinocyte-specific Fn14 knockout mice, imiquimod psoriasis model, transcriptomic analysis in human keratinocytes, recombinant cytokine stimulation\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific genetic knockout with histological and transcriptomic readouts plus in vitro mechanistic dissection of TWEAK/TNF/IL-17 synergy\",\n      \"pmids\": [\"34797693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TWEAK secreted by Th17 cells promotes epithelial-mesenchymal transition (EMT) and colorectal cancer liver metastasis by binding Fn14 on tumor cells, activating downstream migration and invasion. CRISPR knockout or siRNA-mediated knockdown of Fn14 in tumor cells reduced metastasis and prolonged survival in mouse models.\",\n      \"method\": \"CRISPR-Cas9 Fn14 knockout, siRNA knockdown with lipid nanoparticles, mouse metastasis models, single-cell RNA sequencing, Tnfsf12-knockout mice\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic perturbations (CRISPR KO, siRNA, Tnfsf12-KO mice) with in vivo metastasis readouts in a single study\",\n      \"pmids\": [\"38335276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TWEAK increases SIRT1 expression and promotes p53 deacetylation in activated hepatic stellate cells (LX-2), suppressing cellular senescence (SA-β-Gal activity); Fn14 membrane expression was markedly upregulated by TWEAK, which enhanced cell viability.\",\n      \"method\": \"Western blotting for SIRT1 and ac-p53, RT-PCR, SA-β-Gal senescence assay, Fn14 expression quantification\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single cell line, western blotting and senescence staining without pathway-specific knockdown to confirm mechanism\",\n      \"pmids\": [\"27888541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TWEAK/Fn14 signaling in Prominin-1-expressing hepatic progenitor cells activates non-canonical NF-κB signaling, driving profibrogenic ductular reactions in biliary atresia. Fn14 antagonism decreased ductular reactions, biliary fibrosis, and periportal fibroblast activation in a mouse model; recombinant TWEAK accelerated murine HPC organoid growth, an effect abolished by Fn14 antagonism.\",\n      \"method\": \"Fn14 antagonist (L524-0366) in vivo, murine HPC organoid proliferation assay with recombinant TWEAK and antagonist, immunohistochemistry, non-canonical NF-κB pathway western blotting\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological Fn14 blockade in vivo combined with organoid rescue assay, single lab\",\n      \"pmids\": [\"36626628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TWEAK/Fn14 activation in bullous pemphigoid keratinocytes (HaCaT cells) reduces BP180 expression and cellular adherence via ERK and NF-κB pathway activation and downstream ADAM17 activity; ADAM17 siRNA knockdown preserved BP180 and protected cell adherence.\",\n      \"method\": \"Fn14 siRNA, ADAM17 siRNA, ERK and NF-κB pathway inhibition, BP180 expression by western blot, cell adherence assay\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown of Fn14 and ADAM17 with functional adherence readout, single lab\",\n      \"pmids\": [\"28351660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Constitutive Fn14 signaling in TNBC rewires the epigenomic landscape by activating TNBC-specific super-enhancers (via chromatin looping) to transcriptionally upregulate NAMPT, driving NAD+/ATP metabolic reprogramming critical for filopodia formation and metastasis.\",\n      \"method\": \"Fn14 constitutive expression/knockdown, super-enhancer mapping (H3K27ac ChIP-seq), chromatin looping assay, NAMPT inhibition, metabolomics (NAD+/ATP), filopodia formation assay, in vivo metastasis model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP-seq, chromatin looping, metabolomics, and in vivo models in a single study identifying a mechanistic epigenomic-metabolic axis downstream of Fn14\",\n      \"pmids\": [\"38965263\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TWEAK (TNFSF12) is a type II transmembrane cytokine that is shed as a biologically active soluble form and signals primarily through its receptor Fn14 (TNFRSF12A), which recruits TRAFs 1, 2, and 3 to activate canonical and non-canonical NF-κB pathways, MAPKs (ERK, JNK, p38), JAK2/STAT3, and PI3K/AKT; TWEAK can also be scavenged by CD163 on macrophages; depending on cellular context and co-stimulatory signals, TWEAK/Fn14 engagement drives proliferation (liver progenitor/oval cells, keratinocytes, myoblast fusion via non-canonical NF-κB), caspase-dependent apoptosis or cathepsin B-dependent necrosis, necroptosis (via RIPK1/RIPK3/MLKL), inflammation (via chemokine/cytokine induction, EGFR transactivation through ADAM17, and HMGB1 upregulation), epigenetic repression of Klotho and PGC-1α through RelA-directed histone deacetylation, and in cancer cells activates super-enhancer-driven NAMPT/NAD+ metabolic reprogramming to promote metastasis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TNFSF12 (TWEAK) is a type II transmembrane cytokine of the TNF superfamily that is shed as a biologically active soluble ligand and signals through the small TNF-receptor-family member Fn14/TweakR (TNFRSF12A), to which it binds with nanomolar affinity and whose cytoplasmic tail recruits TRAFs 1, 2, and 3 [#0, #18]. Engagement of Fn14 drives context-dependent outcomes spanning proliferation, cell death, inflammation, and metabolic/epigenetic reprogramming. TWEAK is mitogenic for tissue progenitor cells, expanding liver oval/progenitor cells in an Fn14-dependent manner [#3] and promoting hepatic progenitor ductular reactions and myoblast fusion through low-dose activation of the non-canonical NF-\\u03baB pathway (NIK/IKK\\u03b1/p100/RelB) [#6, #22]. In parallel, TWEAK triggers cell-type-specific death programs\\u2014caspase-8/3-dependent apoptosis, cathepsin B-dependent necrosis upon caspase inhibition [#2], and an Fn14/RIPK3/MLKL-dependent late wave of necroptosis in injured renal tubules [#9]\\u2014while an early study showed that in some lines TWEAK-induced apoptosis is relayed indirectly through endogenous TNF/TNFR1 signaling [#1]. As a pro-inflammatory effector, TWEAK activates canonical NF-\\u03baB, MAPK (ERK/JNK/p38) and AP-1, JAK2/STAT3, and PI3K pathways to induce chemokines, cytokines, HMGB1, endothelin-1/ECE-1, and VEGF, and transactivates EGFR via ADAM17-mediated shedding of HB-EGF/TGF\\u03b1 [#7, #11, #12, #13, #14], with TRAF3IP2 acting as a causal amplifying intermediate in cardiac fibroblasts [#10]. TWEAK also reprograms cellular state by directing RelA-dependent histone deacetylation at the Klotho and PGC-1\\u03b1 promoters to repress these genes and impair mitochondrial function [#5, #8], and in triple-negative breast cancer drives super-enhancer activation of NAMPT to enable NAD+/ATP metabolic reprogramming and metastasis [#24]. Soluble TWEAK can be scavenged by the macrophage receptor CD163, which competes with Fn14 for ligand binding and limits TWEAK-driven tumor cell apoptosis [#4]. Pathologically, TWEAK/Fn14 contributes to psoriatic skin inflammation through synergy with TNF and IL-17A [#19] and promotes colorectal cancer EMT and liver metastasis when secreted by Th17 cells [#20].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that TWEAK-induced death in some cells is not cell-intrinsic but relayed through endogenous TNF/TNFR1, and that TWEAK acts via a receptor other than the death-domain receptor DR3.\",\n      \"evidence\": \"Neutralizing antibody and TNFR1-Fc blockade plus RT-PCR for receptor expression in Kym-1 cells\",\n      \"pmids\": [\"10382740\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The non-death-domain TWEAK receptor was undefined at this stage\", \"Did not identify Fn14 as the direct receptor\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified Fn14/TweakR as the high-affinity TWEAK receptor and defined its proximal signaling machinery, resolving the previously undefined receptor and linking TWEAK to angiogenesis and endothelial growth.\",\n      \"evidence\": \"Receptor cloning, five orthogonal binding assays (Kd ~2.3 nM), TRAF1/2/3 pulldowns, HUVEC proliferation/migration and in vivo corneal angiogenesis\",\n      \"pmids\": [\"11728344\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional outputs not mapped\", \"TRAF-to-NF-\\u03baB coupling not yet dissected\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed that TWEAK engages multiple distinct death pathways in a cell-type-specific manner, establishing mechanistic bifurcation between caspase-dependent apoptosis and cathepsin B-dependent necrosis.\",\n      \"evidence\": \"Caspase activity assays, pharmacological caspase/cathepsin inhibitors, and cathepsin B subcellular fractionation across HSC3 and HT-29 lines\",\n      \"pmids\": [\"11777967\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity confirmed only as non-DR3, not directly Fn14\", \"Molecular switch controlling apoptosis-vs-necrosis not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Confirmed TWEAK as a type II transmembrane protein shed as an active soluble cytotoxic cytokine acting on Fn14-expressing targets.\",\n      \"evidence\": \"cDNA transfection, macrophage secretion, cytotoxicity and mAb neutralization assays; review synthesis of cloning/binding data\",\n      \"pmids\": [\"12821115\", \"12787562\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Sheddase responsible for soluble TWEAK generation not identified\", \"Quantitative contribution of membrane vs soluble form unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated genetically that TWEAK is a selective progenitor-cell mitogen acting through Fn14, establishing a regenerative/proliferative role distinct from its death-inducing activity.\",\n      \"evidence\": \"Fn14-null and transgenic mice, adenoviral TWEAK, anti-TWEAK mAb, and oval cell proliferation assays\",\n      \"pmids\": [\"16110324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling driving oval cell proliferation not defined here\", \"Selectivity for progenitors over mature hepatocytes mechanistically unexplained\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified CD163 as an alternate scavenger receptor that competes with Fn14 for TWEAK, introducing a ligand-sequestration mechanism that tunes TWEAK availability.\",\n      \"evidence\": \"Competition binding assays, CHO transfection binding, and monocyte sequestration reversing tumor cell apoptosis\",\n      \"pmids\": [\"17548657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological significance of CD163 scavenging in vivo not established\", \"Whether CD163 transduces signal or only sequesters unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Revealed an epigenetic repressive arm of TWEAK signaling, where RelA directs histone deacetylation at the Klotho promoter to downregulate the gene.\",\n      \"evidence\": \"ChIP for RelA occupancy and histone deacetylation, NF-\\u03baB/HDAC inhibitors, and in vivo TWEAK/anti-TWEAK in tubular cells\",\n      \"pmids\": [\"21719790\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific HDAC recruited not identified\", \"Generality beyond renal tubular cells not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the non-canonical NF-\\u03baB (NIK/IKK\\u03b1/p100/RelB) pathway as the low-dose TWEAK output controlling myoblast fusion, separating it from canonical NF-\\u03baB signaling.\",\n      \"evidence\": \"Genetic knockdown of p100/RelB/IKK\\u03b1/NIK, cIAP1 knockout, and multinucleation assays\",\n      \"pmids\": [\"23074266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dose threshold mechanism switching canonical vs non-canonical not molecularly defined\", \"Fusion machinery targets downstream of RelB unidentified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Dissected TWEAK-driven inflammation into EGFR-dependent and -independent arms, identifying ADAM17-mediated EGFR ligand shedding as a transactivation route to ERK and proinflammatory genes.\",\n      \"evidence\": \"Erlotinib and ADAM17 inhibitor treatment in vivo and in vitro with phospho-EGFR/ERK readouts; HMGB1/PI3K-NF-\\u03baB dissection in M1 macrophages\",\n      \"pmids\": [\"24037740\", \"23288170\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of Fn14-to-ADAM17 coupling not defined\", \"HMGB1 study (#11) is Medium-confidence single-lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended the epigenetic repression model to PGC-1\\u03b1, linking TWEAK/NF-\\u03baB-directed histone deacetylation to mitochondrial dysfunction, and revealed AP-1/NF-\\u03baB-driven endothelin induction.\",\n      \"evidence\": \"ChIP for H3 deacetylation at PGC-1\\u03b1 promoter, PGC-1\\u03b1 rescue, mitochondrial membrane potential; ECE-1 promoter mapping and EMSA for the endothelin axis\",\n      \"pmids\": [\"26535995\", \"28025386\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endothelin/SIRT1 findings vary in confidence and tissue\", \"Connection between mitochondrial repression and cell fate not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established TWEAK/Fn14 as a driver of RIPK1/RIPK3/MLKL-dependent necroptosis and of TRAF3IP2-amplified pro-fibrotic and JAK2/STAT3-hypertrophic responses, broadening the cell-fate and tissue-remodeling repertoire.\",\n      \"evidence\": \"RIPK3/MLKL/Fn14 knockouts and necrostatin-1 in AKI; TRAF3IP2 KO/siLNA in cardiac fibroblasts; JAK2/STAT3/Fn14 siRNA in atrial myocytes\",\n      \"pmids\": [\"29588419\", \"29981796\", \"29971943\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What dictates necroptosis vs apoptosis timing in tissue not fully resolved\", \"TRAF3IP2 positive-feedback initiation trigger unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated cell-type-specific, genetically defined roles for Fn14 in epithelial pathology\\u2014keratinocyte-driven psoriatic inflammation via TWEAK/TNF/IL-17A synergy and hepatic progenitor non-canonical NF-\\u03baB-driven biliary fibrosis.\",\n      \"evidence\": \"Keratinocyte-specific Fn14 KO in imiquimod model with keratinocyte transcriptomics; Fn14 antagonist and HPC organoid rescue in biliary atresia model\",\n      \"pmids\": [\"34797693\", \"36626628\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of TWEAK/TNF/IL-17 transcriptional synergy not fully mapped\", \"Progenitor-specific signaling components incompletely defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Uncovered an oncogenic epigenomic-metabolic axis in which Fn14 activates super-enhancers to upregulate NAMPT-driven NAD+/ATP metabolism enabling metastasis, and showed Th17-derived TWEAK drives EMT and colorectal liver metastasis.\",\n      \"evidence\": \"H3K27ac ChIP-seq, chromatin looping, NAMPT inhibition and metabolomics in TNBC; CRISPR/siRNA Fn14 KO and Tnfsf12-KO mice in CRC metastasis models\",\n      \"pmids\": [\"38965263\", \"38335276\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Fn14 signaling reaches super-enhancer machinery not mechanistically resolved\", \"Therapeutic targetability of the TWEAK-NAMPT axis untested clinically\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single TWEAK/Fn14 axis selects among proliferation, apoptosis, necroptosis, inflammation, and epigenetic/metabolic reprogramming\\u2014and what molecular thresholds (ligand dose, cIAP/TRAF state, co-stimulatory context) govern the switch\\u2014remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking receptor occupancy to fate choice\", \"Sheddase generating soluble TWEAK and its regulation undefined\", \"In vivo balance between Fn14 signaling and CD163 scavenging unquantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 17, 18]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [17, 18]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [17, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 6, 7, 12]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 9]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11, 12, 19]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [5, 8, 24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [20, 24]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TNFRSF12A\", \"CD163\", \"TRAF1\", \"TRAF2\", \"TRAF3\", \"TRAF3IP2\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}